denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Hematology Disease Topics & Pathways:
Workforce, Plasma Cell Disorders, Combination therapy, Diseases, Therapies, Lymphoid Malignancies
Description:
Multiple Myeloma is the second most common hematologic malignancy in the United States with almost 35,000 new diagnosis a year. For many patients, progression to multiple myeloma is a step wise process from Monoclonal gammopathy of undetermined significance (MGUS) to Smoldering multiple Myeloma(SMM) to Multiple Myeloma(MM). In the era of risk stratification, the question of whether to treat certain SMM is of great importance. In addition, in the era of novel agents and many combination therapies in the newly diagnosed MM (NDMM) and relapsed MM (RMM), how do we make sense of the menu in NDMM and how do we pick the next best regimen in first relapse/progression of MM?
Dr. Sigrun Thorsteinsdottir will discuss the epidemiology and diagnosis of smoldering multiple myeloma (SMM). She will discuss various risk stratification models in SMM, previous treatment trials, as well as ongoing trials. She will outline the current dilemma about treatment initiation in SMM and the arguments for and against starting anti-myeloma treatment at the SMM stage, and finally present how to approach the clinical management of SMM patients.
Dr. Caitlin Costello will focus on the modern approach to choosing the optimal therapy for a patient with newly diagnosed multiple myeloma. In an era where there are seemingly an abundance of novel drugs and combinations, it can be difficult to know the ideal treatment to choose. Multiple factors must be considered when choosing a personalized approach with the ultimate goal to provide a deep and durable remissions from the outset.
Dr. Yvonne Efebera will talk about factors to consider in choosing the next best regimen in MM patients at first relapse. Patient-related factors, Disease-related factors and Treatment-related factors. Patient factors such as functional age, performance status/frailty, comorbidities and healthcare related goals and preferences; disease related factors such as aggressiveness of progression, time to relapse from initial diagnosis or autologous stem cell transplant, bone marrow reserve at time of progression; treatment related such as response to initial treatment, length of response, and initial regimen used, all will impact choice of regimen used at first relapse/progression.
Dr. Sigrun Thorsteinsdottir will discuss the epidemiology and diagnosis of smoldering multiple myeloma (SMM). She will discuss various risk stratification models in SMM, previous treatment trials, as well as ongoing trials. She will outline the current dilemma about treatment initiation in SMM and the arguments for and against starting anti-myeloma treatment at the SMM stage, and finally present how to approach the clinical management of SMM patients.
Dr. Caitlin Costello will focus on the modern approach to choosing the optimal therapy for a patient with newly diagnosed multiple myeloma. In an era where there are seemingly an abundance of novel drugs and combinations, it can be difficult to know the ideal treatment to choose. Multiple factors must be considered when choosing a personalized approach with the ultimate goal to provide a deep and durable remissions from the outset.
Dr. Yvonne Efebera will talk about factors to consider in choosing the next best regimen in MM patients at first relapse. Patient-related factors, Disease-related factors and Treatment-related factors. Patient factors such as functional age, performance status/frailty, comorbidities and healthcare related goals and preferences; disease related factors such as aggressiveness of progression, time to relapse from initial diagnosis or autologous stem cell transplant, bone marrow reserve at time of progression; treatment related such as response to initial treatment, length of response, and initial regimen used, all will impact choice of regimen used at first relapse/progression.